Article

Converting non-neutralizing SARS-CoV-2 antibodies targeting conserved epitopes into broad-spectrum inhibitors through receptor blockade

2022-01-25

Abstract excerpt

All but one of the authorized monoclonal antibody-based treatments for SARS-CoV-2 are largely ineffective against Omicron, highlighting the critical need for biologics capable of overcoming SARS-CoV-2 evolution. These mostly ineffective therapeutic antibodies target epitopes that are not highly conserved. Here we describe broad-spectrum SARS-CoV-2 inhibitors developed by tethering the SARS-CoV-2 receptor, angioten...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dc1a78dd-3f4f-5b90-877a-e4c5c071dca9
DOI: 10.1101/2022.01.24.477625

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Converting non-neutralizing SARS-CoV-2 antibodies targeting conserved epitopes into broad-spectrum inhibitors through receptor blockadeDOI 10.1101/2022.01.24.477625Read

Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitorsSemantic proximity Read

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitopeSemantic proximity Read

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.Semantic proximity Read

A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variantsSemantic proximity Read

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.Semantic proximity Read

DESIGN OF A CHIMERIC ACE-2/Fc-SILENT FUSION PROTEIN WITH ULTRAHIGH AFFINITY AND NEUTRALIZING CAPACITY FOR SARS-CoV-2 VARIANTSSemantic proximity Read

A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variantsSemantic proximity Read

Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variantsSemantic proximity Read

David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitorsSemantic proximity Read

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variantsSemantic proximity Read

Characterisation of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV2 variantsSemantic proximity Read

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecovirusesSemantic proximity Read